Evaluation of RC28-E Injection in Diabetic Macular Edema

Phase 2 Completed 156 enrolled RemeGen Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with diabetic macular edema.

Timeline

Start: 2021-03-17
Primary completion: 2023-07-31
Completion: 2023-07-31

Publications

Zhang W, Cheng S, Gu X, Liu X, Dai H, Zhuang W, Sun B, Gao L, Sun X, Zhang M, Song Z, Wang W, Li L, Chen H, Fang J, Chen Y. Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial. Br J Ophthalmol. 2025 Jun 23;109(7):784-790. doi: 10.1136/bjo-2024-326006.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Conbercept	Protein / enzyme biologic	0.5 mg	Intravitreal
Subject	RC28-E	Protein / enzyme biologic	1 mg	Intravitreal
Subject	RC28-E	Protein / enzyme biologic	2 mg	Intravitreal

Evaluation of RC28-E Injection in Diabetic Macular Edema

Summary

Timeline

Publications

Drugs

Indications